Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2010-10-19 Board/Management Inform…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis CEO Resumes Office 1 page ?Kb
Board/Management Information Classification · 95% confidence The document is a media release dated 20 October 2010 announcing that the Chief Executive Officer of Pharmaxis Ltd has resumed office after medical leave. It contains no financial data, no regulatory form references, no voting results, no legal proceedings, no capital changes, and no detailed financial or management reports. The document is a brief announcement about management status, specifically the CEO's return. This fits the category of Board/Management Information (MANG), which covers announcements of changes or updates in senior management. The document length is short (2362 characters), and it is not an announcement of a report publication or a certification. Therefore, the best classification is MANG with high confidence.
2010-10-19 English
Chairman`s Address to 2010 AGM 2 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Pharmaxis Ltd 2010 Annual General Meeting Chairman’s Address' and contains a speech by the Chairman delivered at the Annual General Meeting (AGM). It discusses company milestones, product approvals, clinical trials, acquisitions, and management updates, which are typical contents of an AGM Chairman's address. There is no detailed financial data or comprehensive financial statements present, so it is not an Annual Report (10-K) or Interim Report (IR). The document is a presentation or speech given at the AGM, fitting the category of AGM Information (AGM-R). The document length is about 5,138 characters, consistent with a detailed AGM address rather than a brief announcement or regulatory filing.
2010-10-19 English
CEO Presentation to 2010 AGM 36 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed presentation including company overview, clinical trial phases, product pipeline, regulatory status, marketing plans, and clinical data for Bronchitol and other products. It references the Annual General Meeting (AGM) in October 2010 and contains extensive information on clinical trials, regulatory submissions, and commercial strategies. The content is typical of an investor presentation aimed at providing comprehensive information about the company's products, clinical progress, and market plans to investors. It is not a formal annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed content support classification as an Investor Presentation rather than a brief announcement or report publication notice.
2010-10-19 English
Results of Meeting 2 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a letter addressed to the Australian Securities Exchange regarding the outcomes of resolutions at the Annual General Meeting (AGM) of Pharmaxis Ltd held on 20 October 2010. It details the voting results on various resolutions including the remuneration report, reappointment of directors, and grant of performance rights. The content focuses on the official results of shareholder votes at the AGM, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements. The document length is 3041 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM presentation or annual report. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2010-10-19 English
Appendix 3B - Option Issue 11 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules and the Corporations Act, indicating it is an official announcement related to securities issuance. It details the issuance of unlisted employee options (Performance Rights), number of securities issued, terms of the securities, and application for quotation on the ASX. The document is structured as a formal announcement of new securities issued and their terms, including warranties and agreements related to the quotation of these securities. There is no financial performance data, earnings information, or management discussion. The document is not a report but an announcement of a capital market transaction involving new securities issuance and quotation application. This fits the definition of a Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issued, consistent with a capital/financing update filing rather than a brief notice or regulatory filing.
2010-10-19 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options held before and after the change, the nature of the change (grant of employee options), and dates of changes. This is a clear report of personal share transactions by a company director. The document length is 3302 characters, which is consistent with a detailed director's dealing notice rather than a brief announcement or other report type. Therefore, the document fits the definition of Director's Dealing (DIRS).
2010-10-19 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.